Prosecution Insights
Last updated: November 22, 2026
Application No. 18/817,850

METHODS FOR CHARACTERIZING A PROTEIN OF INTEREST

Non-Final OA §102§103
Filed
Aug 28, 2024
Priority
Aug 29, 2023 — provisional 63/535,227
Examiner
XU, XIAOYUN
Art Unit
1797
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Regeneron Pharmaceuticals Inc.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
711 granted / 1188 resolved
-5.2% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
51 currently pending
Career history
1252
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
64.9%
+24.9% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
13.6%
-26.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1188 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 17 and 19-20 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wdowiak et al. (Bioconjugate Chemistry, 2021) (Wdowiak). Regarding claim 17, Wdowiak teaches a method for characterizing a protein of interest in a first sample (abstract), the method comprising: forming an alkylated product by either: alkylating the protein of interest with a carbon 13 substituted NEM analog to form a 13C-NEM analog alkylated protein of interest (page 1663, par 6) or alkylating a peptide digest of the protein of interest with a carbon 13 substituted NEM analog to form a 13CNEM analog alkylated peptide digest. Since claim 17 recites alternative alkylation methods connected by “or,” disclosure of the first alternative is sufficient to satisfy the claimed limitation. Wdowiak expressly teaches alkylating a protein with the carbon-13 substituted ICMAT-3 (16*) to form an alkylated protein product. Regarding claim 19, Wdowiak teaches further comprising: subjecting the alkylated product to analysis using liquid chromatography-mass spectrometry to characterize the protein of interest (page 1664. par 2), Regarding claim 20, Wdowiak teaches the alkylated product obtained by the method of claim 17 (page 1663, par 6). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Wdowiak et al. (Bioconjugate Chemistry, 2021) (Wdowiak) in view of Schueffl et al. (Chemical Science, 2021) (Schueffl). Regarding claim 18, Wdowiak teaches alkylating proteins with carbon-13-labeled ICMAT-3 (16*) (page 1663, “Labeling of Lysozyme Standards”: “DMSO solutions of ICMATs (5 mM) (7, 7*, 16, and 16*) were stored at −20 °C. Aliquots of reduced lysozyme solution (400 μL, containing 40 μg lysozyme) were alkylated by the addition of 16 μL of 5 mM ICMAT solution (i.e., each ICMAT was added to a separate aliquot of reduced lysozyme at a ratio of 2 nmol ICMAT/μg lysozyme), followed by vigorous vortexing at room temperature for 1 h.”). However, Wdowiak does not expressly disclose wherein the carbon 13 substituted NEM analog comprises ¹³C₄-maleimide, because Wdowiak's ICMAT-3 (16*) contains a ¹³C₆-labeled phenylene linker rather than a ¹³C₄-labeled maleimide ring (page 1655, Scheme 2). Schueffl teaches carbon-13 labeling of all four carbon atoms of a maleimide ring (page 12595: “To this end, the maleimide moiety and the diaminocyclohexane (DACH) ligand were ¹³C- and ²H-labeled, respectively (Fig. 5A). In more detail, ¹³C₇,¹⁵N-labelled maleimidopropionic acid was synthesized from β-alanine–¹³C₃,¹⁵N and maleic anhydride-¹³C₄, while the deuterium-labelled oxaliplatin was synthesized in six steps starting from D10-cyclohexene based on a protocol for similar compounds.”; see also Figure 5A, page 12596) (Schueffl's labeled maleimide derivative contains four carbon-13 atoms in its maleimide ring). It would have been obvious to one of ordinary skill in the art before the effective filing date to modify Wdowiak's carbon-13-labeled ICMAT-3 by incorporating the ¹³C₄-labeled maleimide ring taught by Schueffl, motivated to improve mass-spectrometric discrimination of isotope-labeled peptides by providing additional mass separation while retaining the thiol-reactive maleimide functionality. Wdowiak teaches that carbon-13 labeling provides favorable chromatographic coelution of corresponding light- and heavy-labeled peptides (page 1657, “Evaluation of 12C/13C-Labeled ICMAT-3”). Schueffl demonstrates that carbon-13 atoms can be incorporated into the maleimide ring itself (page 12595 and Figure 5A). A skilled artisan would have reasonably expected that substituting carbon-13 for naturally occurring carbon in Wdowiak's maleimide ring would preserve its chemical connectivity and thiol-alkylating functionality while increasing the mass difference detectable by mass spectrometry. Allowable Subject Matter Claim 1-16 are allowed. The following is a statement of reasons for the indication of allowable subject matter: While Robotham et al. and Pu et al. disclose differential labeling of free thiols using paired light and heavy isotope-labeled NEM reagents followed by enzymatic digestion and LC-MS analysis, Wdowiak et al. disclose corresponding light and heavy isotope-labeled maleimide analogs, and Gao et al. disclose isotope labeling of peptides after enzymatic digestion, the prior art of record, either alone or in combination, fails to teach or suggest alkylating a protein of interest with a NEM analog or its heavy isotope-substituted form, digesting the alkylated protein with at least one digestive enzyme to form a peptide digest, and subsequently alkylating the peptide digest with the corresponding differential alkylating agent, followed by LC-MS analysis to quantify site-specific free thiols in the original sample. In particular, the prior art does not teach or suggest separating the paired differential alkylation steps by enzymatic digestion in the claimed sequence. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to XIAOYUN R XU, Ph. D. whose telephone number is (571)270-5560. The examiner can normally be reached M-F 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lyle Alexander can be reached at 571-272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /XIAOYUN R XU, Ph.D./ Primary Examiner, Art Unit 1797
Read full office action

Prosecution Timeline

Aug 28, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12800589
METHODS AND SYSTEMS OF PROTEOME ANALYSIS AND IMAGING
3y 5m to grant Granted Nov 17, 2026
Patent 12797850
HANDLING DEVICE AND FLUID HANDLING SYSTEM
3y 3m to grant Granted Nov 17, 2026
Patent 12797844
DEVICE FOR ASSAY SYSTEM, SYSTEM AND METHOD
2y 9m to grant Granted Nov 17, 2026
Patent 12774959
METHOD FOR SENSING METHYL SALICYLATE, METHYL SALICYLATE SENSOR, AND METHOD FOR DETECTING PATHOGEN INFECTION OF PLANTS
3y 1m to grant Granted Oct 27, 2026
Patent 12767984
METHODS AND SYSTEMS TO PERFORM GENETICALLY VARIANT PROTEIN ANALYSIS, AND RELATED MARKER GENETIC PROTEIN VARIATIONS AND DATABASES
6y 7m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
91%
With Interview (+31.6%)
3y 3m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1188 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month